Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

June 24, 2021 13:13 ET | Source: Sorrento Therapeutics, Inc.

Sorrento Receives EUA Approval and Import License From Mexico Authority COFEPRIS For COVI-STIX™ (COVID-19 Virus Rapid Antigen Detection Test) and Plans Product Launch With Initial Shipments in July

Sorrento received official EUA registration and product import license: COFEPRIS EUA registration number “OFICIO: CAS/10720/2021”.Sorrento is establishing its “Sorrento Mexico Ltd” subsidiary to...
June 22, 2021 13:46 ET | Source: Sorrento Therapeutics, Inc.

Sorrento Enters Into Multi-Year Cooperative Research and Development Agreement With the U.S. Naval Medical Research Unit – No. 3 (NAMRU-3) For Pandemic Preparedness Combating COVID-19

Broad multi-year agreement between Sorrento Therapeutics and U.S. Naval Medical Research Unit – No. 3 (NAMRU-3) headquartered in Sigonella, Italy with Laboratory Detachments in Cairo, Egypt, Camp...
June 22, 2021 09:00 ET | Source: Sorrento Therapeutics, Inc.

Sorrento Announces Phase 2 Abivertinib Clinical Studies Have Completed Patient Enrollment in USA and Brazil with Top-Line Clinical Data Expected End of 3Q21

Phase 2 US clinical trial of Abivertinib randomized last patient (#96) on 4/07/2021.Phase 2 Brazilian clinical trial of Abivertinib randomized last patient (#400) on 06/20/2021.Studies are...
June 11, 2021 16:11 ET | Source: Sorrento Therapeutics, Inc.

Sorrento Receives Authorization From the UK Regulatory Agency to Conduct a Phase 2 Clinical Trial for COVI-DROPS in an Outpatient Setting

Large Phase 2 efficacy trial cleared to start in the United Kingdom in newly diagnosed SARS-CoV-2 infected patients.COVI-DROPS is administered by intranasal drops and the antibody is active against...
June 11, 2021 09:00 ET | Source: Sorrento Therapeutics, Inc.

Sorrento Announces Clinical Research Agreement With Mayo Clinic and FDA Clearance for the First Phase 1b Pilot Study Using Sofusa Lymphatic Drug Delivery Technology to Deliver Ipilimumab in Patients With Melanoma

SAN DIEGO, June 11, 2021 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (Nasdaq: SRNE, "Sorrento") today announced a research collaboration agreement with Mayo Clinic to conduct human clinical...
June 04, 2021 13:00 ET | Source: Sorrento Therapeutics, Inc.

Sorrento and Researchers at Karolinska Institutet Have Signed a Research Collaboration Agreement on iPSC-Derived Dimeric Antigen Receptor-Modified Natural Killer (DAR-NK) Cells With The Vision to Bring “Off-The-Shelf" NK Cell-Based Cancer Treatments Rapidly to Patients

SAN DIEGO and STOCKHOLM, Sweden, June 04, 2021 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (Nasdaq: SRNE, "Sorrento") today announced that the Company has entered into an additional...
June 02, 2021 09:00 ET | Source: Sorrento Therapeutics, Inc.

Sorrento Completes Acquisition of ACEA Therapeutics, Creating a Major Oncology Franchise

AMONG MULTIPLE CLINICAL- AND PRECLINICAL-STAGE NCE (NEW CHEMICAL ENTITY) COMPOUNDS ACQUIRED, ABIVERTINIB IS AN ANCHORING LATE-STAGE DRUG PRODUCT WITH POSITIVE CLINICAL TRIAL RESULTS IN BOTH NON-SMALL...
June 02, 2021 07:00 ET | Source: Sorrento Therapeutics, Inc.

Sorrento Announces Addition of COVI-STIX™ (Covid-19 Virus Rapid Antigen Detection Test) to the Official Mexican Government List of Emergency Use Approved Point of Care Rapid Antigen Tests

COVI-STIX has been added to the official government list of point of care rapid antigen tests useful for the detection of SARS-CoV-2 in Mexico...
May 20, 2021 09:00 ET | Source: Sorrento Therapeutics, Inc.

Brazilian Health Regulatory Agency (ANVISA) Authorizes Sorrento Phase 2 Pivotal Clinical Trial of COVI-MSC™ in Hospitalized COVID-19 Patients With Acute Respiratory Distress Syndrome

Brazil Phase 2 Pivotal clinical trial of COVI-MSC is now authorized to proceed.The study will compare therapy using mesenchymal stem cells to placebo (and standard of care) in 100 COVID-19 patients...
May 19, 2021 21:30 ET | Source: Sorrento Therapeutics, Inc.

Sorrento Reports Positive Initial Result in Dosing of First Enbrel-Non-Responding Rheumatoid Arthritis Patient With the Sofusa® Lymphatic Drug Delivery Device

Sofusa is a drug delivery platform technology which delivers biologic therapies through the skin directly into the lymphatic system with potential to improve efficacy and safety and reduce the...